Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The β-haemoglobinopathies are the most prevalent inherited disorders worldwide. Gene therapy of β-thalassaemia is particularly challenging given the requirement for massive haemoglobin production in a lineage-specific manner and the lack of selective advantage for corrected haematopoietic stem cells. Compound βE/β0-thalassaemia is the most common form of severe thalassaemia in southeast Asian countries and their diasporas. The βE-globin allele bears a point mutation that causes alternative splicing. The abnormally spliced form is non-coding, whereas the correctly spliced messenger RNA expresses a mutated βE-globin with partial instability. When this is compounded with a non-functional β0 allele, a profound decrease in β-globin synthesis results, and approximately half of βE/β0-thalassaemia patients are transfusion-dependent. The only available curative therapy is allogeneic haematopoietic stem cell transplantation, although most patients do not have a human-leukocyte-antigen-matched, geno-identical donor, and those who do still risk rejection or graft-versus-host disease. Here we show that, 33 months after lentiviral β-globin gene transfer, an adult patient with severe βE/β0-thalassaemia dependent on monthly transfusions since early childhood has become transfusion independent for the past 21 months. Blood haemoglobin is maintained between 9 and 10 g dl−1, of which one-third contains vector-encoded β-globin. Most of the therapeutic benefit results from a dominant, myeloid-bia…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, this response was associated with a relative increase in a dominant myeloid clone bearing a lentiviral vector insertion within the HMGA2 gene locus.”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“In the initial study of HSCs transduced with β-globin in patients with β-thalassemia, one patient with βE/β0-thalassemia achieved independence from transfusion [67].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“Lentiviral vector-based gene transfer into CD34 + HSCs has subsequently been applied in the treatment of several genetic diseases, including β-thalassemia [67], X-linked adrenoleukodystrophy [51], metachromatic leukodystrophy [68, 69], and Wiskott-Aldrich Syndrome [70].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“The relative clonal dominance at the HMGA2 locus that was initially observed in 1 patient in the LG001 study of the HPV569 vector spontaneously subsided while that patient maintained stable HbA T87Q levels.”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [20]
In the citing paper
“The feasibility of the addition of a gene to autologous hematopoietic cells using a lentiviral vector was shown previously in a single patient with β-thalassemia who safely discontinued transfusions for more than 6 years with ongoing, sustained β A-T87Q -globin expression.14,20”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [20]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
MicroRNA maturation: stepwise processing and subcellular localization
Lee, Y. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf476 · Cited by 2,478
Position-independent, high-level expression of the human β-globin gene in transgenic mice
Grosveld, F., van Assendelft, G. B., Greaves, D. R., & Kollias, G. (1987) · Cell · doi:10.1016/0092-8674(87)90584-8 · Cited by 1,909 · cited 1×
“To demonstrate that only one integrated vector provirus was present in cells with the HMGA2 IS, three qPCR experiments were simultaneously performed on the same genomic DNA preparation with primers specific for either (1) a ‘HIV gag packaging signal’ DNA sequence (common to all vector provirus regardless of IS); (2) t…”
MethodInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Self-citationHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Self-citationOtt, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Chung, J. H., Whiteley, M., & Felsenfeld, G. (1993) · Cell · doi:10.1016/0092-8674(93)80052-g · Cited by 854
Lin28 promotes transformation and is associated with advanced human malignancies
Viswanathan, S. R., Powers, J. T., Einhorn, W., Hoshida, Y., Ng, T. L., Toffanin, S., O'Sullivan, M., Lu, J., Phillips, L. A., Lockhart, V. L., et al. (2009) · Nature Genetics · doi:10.1038/ng.392 · Cited by 814
Long-Term Propagation of Distinct Hematopoietic Differentiation Programs In Vivo
Dykstra, B., Kent, D., Bowie, M., McCaffrey, L., Hamilton, M., Lyons, K., Lee, S.-J., Brinkman, R., & Eaves, C. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.05.015 · Cited by 609
Correction of sickle cell disease in transgenic mouse models by gene therapy
Pawliuk, R., Westerman, K. A., Fabry, M. E., Payen, E., Tighe, R., Bouhassira, E. E., Acharya, S. A., Ellis, J., London, I. M., Eaves, C. J., et al. (2001) · Science · doi:10.1126/science.1065806 · Cited by 579
Self-citationMay, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M. (2000) · Nature · doi:10.1038/35017565 · Cited by 567 · cited 1×
“Numbers along the top indicate blood progenitors from a b-thalassaemic control individual (1), patient P2’s blood progenitors 27 months posttransplantation showing a band consistent with truncated fusion protein of 135 amino acids (2), recombinant truncated (73 amino acids) (4) and fulllength (109 amino acids) (5) hum…”
Background
Cited by
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
“Lentiviral vectors harboring multiple regulatory elements to direct high-level, erythroid-specific hemoglobin expression have been developed (26) and in case reports have shown promise in patients with b-thalassemia or sickle cell disease (120, 121), with larger multicenter clinical trials ongoing (Table 1).”
Gene therapy clinical trials worldwide to 2012 – an update
Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R., & Wixon, J. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2698 · Cited by 1,159
“appeared to be mediated by a dominant clone containing an integration site within the HMGA2 gene [47].”
BackgroundGene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. (2013) · Science · doi:10.1126/science.1233158 · Cited by 1,180
Self-citationLentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M. C., et al. (2013) · Science · doi:10.1126/science.1233151 · Cited by 1,025
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
Clinical use of lentiviral vectors
Milone, M. C., & O’Doherty, U. (2018) · Leukemia · doi:10.1038/s41375-018-0106-0 · Cited by 930
“patient with β/β-thalassemia achieved independence from transfusion [67].”
BackgroundGene therapy clinical trials worldwide to 2017: An update
Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M., & Abedi, M. R. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3015 · Cited by 903
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., et al. (2016) · Nature · doi:10.1038/nature20134 · Cited by 864
Taher, A. T., Weatherall, D. J., & Cappellini, M. D. (2018) · The Lancet · doi:10.1016/s0140-6736(17)31822-6 · Cited by 807
State-of-the-art gene-based therapies: the road ahead
Kay, M. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2971 · Cited by 666
“In a recent study, the transduction of haematopoietic progenitor cells with a lentiviral vector expressing a β-globin cDNA successfully reversed the transfusion dependency of one patient with β-thalassaemia-based anaemi”
BackgroundGene therapy in a patient with sickle cell disease
Ribeil, J.-A., Hacein-Bey-Abina, S., Payen, E., Magnani, A., Semeraro, M., Magrin, E., Caccavelli, L., Neven, B., Bourget, P., El Nemer, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609677 · Cited by 696
Self-citationGene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684
Self-citationDecade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
Scholler, J., Brady, T. L., Binder-Scholl, G., Hwang, W.-T., Plesa, G., Hege, K. M., Vogel, A. N., Kalos, M., Riley, J. L., Deeks, S. G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003761 · Cited by 652
“The durable persistence of the CD4ζ T-cells provided a unique opportunity to interrogate selection for preferred gammaretroviral integration sites over time in T cells, resulting from modulation of cellular growth control genes as a result of integration-mediated events such as distal effects from the LTR enhancer (2)…”
BackgroundMethodInfluentialSelf-citationHuman Umbilical Cord Mesenchymal Stem Cells: A New Era for Stem Cell Therapy
Ding, D.-C., Chang, Y.-H., Shyu, W.-C., & Lin, S.-Z. (2015) · Cell Transplantation · doi:10.3727/096368915x686841 · Cited by 613
“Moreover, the clinical applications of iPSCs have been criticized because of the possibility of forming tumors by integrated oncogenes, particularly c-myc (51), by insertional mutagenesis (28), or by disrupting tumor suppressor genes (3).”
BackgroundWirth, T., Parker, N., & Ylä-Herttuala, S. (2013) · Gene · doi:10.1016/j.gene.2013.03.137 · Cited by 607
High, K. A., & Roncarolo, M. G. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1706910 · Cited by 555
Targeted genome editing in human repopulating haematopoietic stem cells
Genovese, P., Schiroli, G., Escobar, G., Di Tomaso, T., Firrito, C., Calabria, A., Moi, D., Mazzieri, R., Bonini, C., Holmes, M. C., et al. (2014) · Nature · doi:10.1038/nature13420 · Cited by 555
“Hematopoietic Stem Cells (HSC)-based gene therapy has provided therapeutic benefit in primary immunodeficiencies 1,2 , thalassemia 3 and leukodystrophies 4,5 .”
Origa, R. (2017) · Genetics in Medicine · doi:10.1038/gim.2016.173 · Cited by 509
In vivo genome editing restores haemostasis in a mouse model of haemophilia
Li, H., Haurigot, V., Doyon, Y., Li, T., Wong, S. Y., Bhagwat, A. S., Malani, N., Anguela, X. M., Sharma, R., Ivanciu, L., et al. (2011) · Nature · doi:10.1038/nature10177 · Cited by 548
Self-citationSessa, M., Lorioli, L., Fumagalli, F., Acquati, S., Redaelli, D., Baldoli, C., Canale, S., Lopez, I. D., Morena, F., Calabria, A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30374-9 · Cited by 502
Safe harbours for the integration of new DNA in the human genome
Sadelain, M., Papapetrou, E. P., & Bushman, F. D. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3179 · Cited by 441
Self-citationEntering the Modern Era of Gene Therapy
Anguela, X. M., & High, K. A. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-012017-043332 · Cited by 471
“The first successful gene therapy approach in an adult with β-thalassemia was reported in 2010 (26).”
BackgroundParoxysmal nocturnal haemoglobinuria
Hill, A., DeZern, A. E., Kinoshita, T., & Brodsky, R. A. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.28 · Cited by 448
Viral Vectors for Gene Therapy: Translational and Clinical Outlook
Kotterman, M. A., Chalberg, T. W., & Schaffer, D. V. (2015) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-104938 · Cited by 424
Higgs, D. R., Engel, J. D., & Stamatoyannopoulos, G. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60283-3 · Cited by 434
Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease
Esrick, E. B., Lehmann, L. E., Biffi, A., Achebe, M., Brendel, C., Ciuculescu, M. F., Daley, H., MacKinnon, B., Morris, E., Federico, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029392 · Cited by 449
Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease
Kanter, J., Walters, M. C., Krishnamurti, L., Mapara, M. Y., Kwiatkowski, J. L., Rifkin-Zenenberg, S., Aygun, B., Kasow, K. A., Pierciey, F. J., Bonner, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2117175 · Cited by 442
Rachmilewitz, E. A., & Giardina, P. J. (2011) · Blood · doi:10.1182/blood-2010-08-300335 · Cited by 417
“CD34+ cells transduced with a lentiviral vector expressing a βA-787Q globin gene, has remained stable without transfusion support for two years.(103) In addition, a phase 1 study of transfusion-dependent β thalassemia patients using the TNS q.”
MethodSilva, G., Poirot, L., Galetto, R., Smith, J., Montoya, G., Duchateau, P., & Paques, F. (2011) · Current Gene Therapy · doi:10.2174/156652311794520111 · Cited by 410
“One such approach involves self-inactivating (SIN) gammaretrovirus and lentivirus-based vectors, which when integrated lack enhancer and promoter sequences from the LTR [6-13].”
MethodWhat can exome sequencing do for you?
Majewski, J., Schwartzentruber, J., Lalonde, E., Montpetit, A., & Jabado, N. (2011) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2011-100223 · Cited by 394
Xie, F., Ye, L., Chang, J. C., Beyer, A. I., Wang, J., Muench, M. O., & Kan, Y. W. (2014) · Genome Research · doi:10.1101/gr.173427.114 · Cited by 408
“…in the HBB gene, the functional analysis of the corrected HBB was hampered by the fact that erythroid precursors differenti- ated from iPSCs as well as ESC preferentially express embryonic and fetal, but not adult hemoglobinprotein (Chang et al. 2006, 2010; Zou et al. 2011; Ma et al. 2013).”
BackgroundResultAngelucci, E., Matthes-Martin, S., Baronciani, D., Bernaudin, F., Bonanomi, S., Cappellini, M. D., Dalle, J.-H., Di Bartolomeo, P., de Heredia, C. D., Dickerhoff, R., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.099747 · Cited by 399
Self-citationEx vivo gene transfer and correction for cell-based therapies
Naldini, L. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2985 · Cited by 358
Lentiviral vectors: basic to translational
Sakuma, T., Barry, M. A., & Ikeda, Y. (2012) · Biochemical Journal · doi:10.1042/bj20120146 · Cited by 336
The stem cell secretome and its role in brain repair
Drago, D., Cossetti, C., Iraci, N., Gaude, E., Musco, G., Bachi, A., & Pluchino, S. (2013) · Biochimie · doi:10.1016/j.biochi.2013.06.020 · Cited by 348
Copley, M. R., Babovic, S., Benz, C., Knapp, D. J. H. F., Beer, P. A., Kent, D. G., Wohrer, S., Treloar, D. Q., Day, C., Rowe, K., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2783 · Cited by 342
Site-specific integration and tailoring of cassette design for sustainable gene transfer
Lombardo, A., Cesana, D., Genovese, P., Di Stefano, B., Provasi, E., Colombo, D. F., Neri, M., Magnani, Z., Cantore, A., Lo Riso, P., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1674 · Cited by 331
“This rule may be applicable to randomly integrating vector”
MethodThe switch from fetal to adult hemoglobin.
Sankaran, V. G., & Orkin, S. H. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011643 · Cited by 333
“These curative therapies still remain largely experimental, although important scientific and clinical advances in these approaches are being made (Hsieh et al. 2009; Cavazzana-Calvo et al. 2010).”
BackgroundCraigie, R., & Bushman, F. D. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006890 · Cited by 327
“However, in a recent lentiviral gene therapy trial that successfully treated b thalassemia major in one human subject, a cell clone expanded that contained an integrated vector in the protooncogene HMGA2 (Cavazzana-Calvo et al. 2010).”
BackgroundSelf-citationCorrection of the sickle cell disease mutation in human hematopoietic stem/progenitor cells
Hoban, M. D., Cost, G. J., Mendel, M. C., Romero, Z., Kaufman, M. L., Joglekar, A. V., Ho, M., Lumaquin, D., Gray, D., Lill, G. R., et al. (2015) · Blood · doi:10.1182/blood-2014-12-615948 · Cited by 320
Ye, L., Wang, J., Beyer, A. I., Teque, F., Cradick, T. J., Qi, Z., Chang, J. C., Bao, G., Muench, M. O., Yu, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407473111 · Cited by 320
“Also, integration mutagenesis by lentiviral vectors could potentially cause other complications (12, 13), and the immunogenicity of adenoviral vectors could eliminate the transduced cells from the recipient (14).”
BackgroundSheridan, C. (2011) · Nature Biotechnology · doi:10.1038/nbt.1769 · Cited by 302
Papapetrou, E. P., Lee, G., Malani, N., Setty, M., Riviere, I., Tirunagari, L. M. S., Kadota, K., Roth, S. L., Giardina, P., Viale, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1717 · Cited by 299
Self-citationVirus-mediated gene delivery for human gene therapy
Giacca, M., & Zacchigna, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.008 · Cited by 302
Kaufmann, K. B., Büning, H., Galy, A., Schambach, A., & Grez, M. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202287 · Cited by 276
Gene Therapies for Cancer: Strategies, Challenges and Successes
Das, S. K., Menezes, M. E., Bhatia, S., Wang, X., Emdad, L., Sarkar, D., & Fisher, P. B. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.24791 · Cited by 284
Production of lentiviral vectors
Merten, O.-W., Hebben, M., & Bovolenta, C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.17 · Cited by 294
Anemia: progress in molecular mechanisms and therapies
Sankaran, V. G., & Weiss, M. J. (2015) · Nature Medicine · doi:10.1038/nm.3814 · Cited by 281
Gaspar, H. B., Cooray, S., Gilmour, K. C., Parsley, K. L., Zhang, F., Adams, S., Bjorkegren, E., Bayford, J., Brown, L., Davies, E. G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002716 · Cited by 285
Programming gene and engineered-cell therapies with synthetic biology
Kitada, T., DiAndreth, B., Teague, B., & Weiss, R. (2018) · Science · doi:10.1126/science.aad1067 · Cited by 281
“This approach allows for efficient ex vivo delivery of genetic material and has seen recent successes in clinical trials, including CAR T cell– based cancer therapies (2) and engineered hematopoietic stem cells used to treat b-thalassemia (1) and adenosine deaminase severe combined immunodeficiency (93).”
BackgroundLentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency
De Ravin, S. S., Wu, X., Moir, S., Kardava, L., Anaya-O’Brien, S., Kwatemaa, N., Littel, P., Theobald, N., Choi, U., Su, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8856 · Cited by 244
The powerful world of antisense oligonucleotides: From bench to bedside
Quemener, A. M., Bachelot, L., Forestier, A., Donnou‐Fournet, E., Gilot, D., & Galibert, M. (2020) · WIREs RNA · doi:10.1002/wrna.1594 · Cited by 280
“The modified cells are then injected back into the patient (Cavazzana-Calvo et al., 2010; Thompson et al., 2018).”
BackgroundJung, Y., Bauer, G., & Nolta, J. A. (2012) · STEM CELLS · doi:10.1002/stem.727 · Cited by 270
Lancet Commission: Stem cells and regenerative medicine
Cossu, G., Birchall, M., Brown, T., De Coppi, P., Culme-Seymour, E., Gibbon, S., Hitchcock, J., Mason, C., Montgomery, J., Morris, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)31366-1 · Cited by 272
Wang, T., Upponi, J. R., & Torchilin, V. P. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.07.013 · Cited by 268
Adoptive Immunotherapy for Cancer or Viruses
Maus, M. V., Fraietta, J. A., Levine, B. L., Kalos, M., Zhao, Y., & June, C. H. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120136 · Cited by 264
Gene therapy using haematopoietic stem and progenitor cells
Ferrari, G., Thrasher, A. J., & Aiuti, A. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-00298-5 · Cited by 254
Fucharoen, S., & Weatherall, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011734 · Cited by 248
“The first successful report of gene therapy in thalassemia involved a patient with HbE b thalassemia (Cavazzana-Calvo et al. 2010).”
BackgroundHematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned
Morgan, R. A., Gray, D., Lomova, A., & Kohn, D. B. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.10.010 · Cited by 245
“The best studied example is the use of multiple elements from the beta-globin gene locus to achieve erythroid-specific expression for the treatment of hemoglobinopathies (Cavazzana-Calvo et al., 2010; May et al., 2000).”
BackgroundMethodAdvantages and applications of CAR-expressing natural killer cells
Glienke, W., Esser, R., Priesner, C., Suerth, J. D., Schambach, A., Wels, W. S., Grez, M., Kloess, S., Arseniev, L., & Koehl, U. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00021 · Cited by 243
“…clonal dominance, i.e., the strong prevalence of a few specific clones dominating hematopoiesis, has also been observed with second generation SIN vectors (Cavazzana-Calvo et al., 2010), arguing for careful vector design and/or additional inclusion of suicide switches even in these vectors.”
BackgroundExosomes as nano-theranostic delivery platforms for gene therapy
Tan, A., Rajadas, J., & Seifalian, A. M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.06.014 · Cited by 242
Clinical development of gene therapy: results and lessons from recent successes
Kumar, S. R., Markusic, D. M., Biswas, M., High, K. A., & Herzog, R. W. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.34 · Cited by 232
Baronciani, D., Angelucci, E., Potschger, U., Gaziev, J., Yesilipek, A., Zecca, M., Orofino, M. G., Giardini, C., Al-Ahmari, A., Marktel, S., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.293 · Cited by 241
Zou, J., Sweeney, C. L., Chou, B.-K., Choi, U., Pan, J., Wang, H., Dowey, S. N., Cheng, L., & Malech, H. L. (2011) · Blood · doi:10.1182/blood-2010-12-328161 · Cited by 236
Gene Insertion Into Genomic Safe Harbors for Human Gene Therapy
Papapetrou, E. P., & Schambach, A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.38 · Cited by 238
Marktel, S., Scaramuzza, S., Cicalese, M. P., Giglio, F., Galimberti, S., Lidonnici, M. R., Calbi, V., Assanelli, A., Bernardo, M. E., Rossi, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0301-6 · Cited by 225
Micklethwaite, K. P., Gowrishankar, K., Gloss, B. S., Li, Z., Street, J. A., Moezzi, L., Mach, M. A., Sutrave, G., Clancy, L. E., Bishop, D. C., et al. (2021) · Blood · doi:10.1182/blood.2021010858 · Cited by 226
Sabatino, D. E., Bushman, F. D., Chandler, R. J., Crystal, R. G., Davidson, B. L., Dolmetsch, R., Eggan, K. C., Gao, G., Gil-Farina, I., Kay, M. A., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.06.004 · Cited by 212
Self-citationMolecular basis of β thalassemia and potential therapeutic targets
Thein, S. L. (2018) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2017.06.001 · Cited by 209
“The most advanced of these is the antisickling β-globin vector containing the HbAT87Q mutation (Bluebird Bio), first tested in a patient with transfusion-dependent HbE/β-thalassemia [144,145].”
The limited application of stem cells in medicine: a review
Poulos, J. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-017-0735-7 · Cited by 209
“Due to the integration of oncogenes in the reprogramming process which can potentially cause cancer by insertional mutagenesis [59] and have been shown to disrupt tumour-suppressing genes [60, 61], iPSCs have a significant tumorigenic potential.”
BackgroundRecent Advances in the Treatment of Sickle Cell Disease
Salinas Cisneros, G., & Thein, S. L. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00435 · Cited by 193
“The unique feature of this vector is that the amino acid substitution (βA−T87Q) allows for high performance liquid chromatography (HPLC) monitoring of the transgene globin levels in the patient’s cells (Cavazzana-Calvo et al., 2010).”
BackgroundUmbilical Cord Blood Transplantation for Children with Thalassemia and Sickle Cell Disease
Ruggeri, A., Eapen, M., Scaravadou, A., Cairo, M. S., Bhatia, M., Kurtzberg, J., Wingard, J. R., Fasth, A., Lo Nigro, L., Ayas, M., et al. (2011) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2011.01.012 · Cited by 208
Gene editing and CRISPR in the clinic: current and future perspectives
Hirakawa, M. P., Krishnakumar, R., Timlin, J. A., Carney, J. P., & Butler, K. S. (2020) · Bioscience Reports · doi:10.1042/bsr20200127 · Cited by 192
“While a number of studies have focused on utilizing genome editors to facilitate the correction of mutations in HBB, or to aid in site specific incorporation of an intact copy of HBB [74–78], others have focused on the editing ability alone.”
BackgroundInfluentialFriedman, K. M., Garrett, T. E., Evans, J. W., Horton, H. M., Latimer, H. J., Seidel, S. L., Horvath, C. J., & Morgan, R. A. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.001 · Cited by 205
Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges
Cavazzana, M., Bushman, F. D., Miccio, A., André-Schmutz, I., & Six, E. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0020-9 · Cited by 199
Self-citationCell-based therapy technology classifications and translational challenges
Mount, N. M., Ward, S. J., Kefalas, P., & Hyllner, J. (2015) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2015.0017 · Cited by 195
“most common being T cells [5,6,18], HSCs [19–23] and MSCs [23–25].”
BackgroundPiel, F. B., Rees, D. C., DeBaun, M. R., Nnodu, O., Ranque, B., Thompson, A. A., Ware, R. E., Abboud, M. R., Abraham, A., Ambrose, E. E., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00096-0 · Cited by 177
Ginzburg, Y., & Rivella, S. (2011) · Blood · doi:10.1182/blood-2011-03-283614 · Cited by 201
Moiani, A., Paleari, Y., Sartori, D., Mezzadra, R., Miccio, A., Cattoglio, C., Cocchiarella, F., Lidonnici, M. R., Ferrari, G., & Mavilio, F. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61852 · Cited by 183
Ye, L., Wang, J., Tan, Y., Beyer, A. I., Xie, F., Muench, M. O., & Kan, Y. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612075113 · Cited by 190
“However, the long-term safety of the known random viral integrations into multiple genomic sites needs to be determined (6, 7).”
BackgroundGenetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease
Hoban, M. D., Orkin, S. H., & Bauer, D. E. (2016) · Blood · doi:10.1182/blood-2015-09-618587 · Cited by 194
“The affected patient achieved transfusion independence without leukemia development, so for this patient the clonal dominance may have provided some advantage in that the corrected cells were present at a high frequency.(128,142) Of note, the causal cryptic 39 splice signal was introduced by rearranged sequences from…”
BackgroundInduction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus
Antoniani, C., Meneghini, V., Lattanzi, A., Felix, T., Romano, O., Magrin, E., Weber, L., Pavani, G., El Hoss, S., Kurita, R., et al. (2018) · Blood · doi:10.1182/blood-2017-10-811505 · Cited by 194
Girard-Gagnepain, A., Amirache, F., Costa, C., Lévy, C., Frecha, C., Fusil, F., Nègre, D., Lavillette, D., Cosset, F.-L., & Verhoeyen, E. (2014) · Blood · doi:10.1182/blood-2014-02-558163 · Cited by 178
Self-citationMerten, O.-W., Charrier, S., Laroudie, N., Fauchille, S., Dugué, C., Jenny, C., Audit, M., Zanta-Boussif, M.-A., Chautard, H., Radrizzani, M., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.060 · Cited by 185
“…gene transfer vectors based on the more complex lentiviruses, such as human immunodeficiency virus (HIV)- 1, have also reached the clinical stage to treat inherited diseases or HIV infection (Levine et al. , 2006; Cartier et al. , 2009; Cavazzana-Calvo et al. , 2010; DiGiusto et al. , 2010).”
Uncovering and Dissecting the Genotoxicity of Self-inactivating Lentiviral Vectors In Vivo
Cesana, D., Ranzani, M., Volpin, M., Bartholomae, C., Duros, C., Artus, A., Merella, S., Benedicenti, F., Sergi Sergi, L., Sanvito, F., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.3 · Cited by 189
Therapeutic strategies for sickle cell disease: towards a multi-agent approach
Telen, M. J., Malik, P., & Vercellotti, G. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0003-2 · Cited by 181
Erythropoiesis: insights into pathophysiology and treatments in 2017
Zivot, A., Lipton, J. M., Narla, A., & Blanc, L. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0011-z · Cited by 163
Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies
Roth, T. L., Li, P. J., Blaeschke, F., Nies, J. F., Apathy, R., Mowery, C., Yu, R., Nguyen, M. L. T., Lee, Y., Truong, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.039 · Cited by 186
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
Stoiber, S., Cadilha, B. L., Benmebarek, M.-R., Lesch, S., Endres, S., & Kobold, S. (2019) · Cells · doi:10.3390/cells8050472 · Cited by 180
“The risk for the insertional activation of oncogenes and consequential malignant transformation may be reduced but is not eliminated by the use of lentiviral vectors [123], with a high incidence of lentiviral vector-associated tumorigenesis having been observed in one in vivo model [124].”
BackgroundHematopoietic Stem Cell Heterogeneity Takes Center Stage
Copley, M. R., Beer, P. A., & Eaves, C. J. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.006 · Cited by 175
“Of interest, in this regard, is a recent b-thalassemia patient who was transplanted with genetically corrected autologous cells and subsequently found to be reconstituted with a long-lived lymphoid-deficient clone (Cavazzana-Calvo et al., 2010).”
BackgroundCord blood-hematopoietic stem cell expansion in 3D fibrin scaffolds with stromal support
Ventura Ferreira, M. S., Jahnen-Dechent, W., Labude, N., Bovi, M., Hieronymus, T., Zenke, M., Schneider, R. K., & Neurs, S. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.06.029 · Cited by 177
Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies
Chabannon, C., Kuball, J., Bondanza, A., Dazzi, F., Pedrazzoli, P., Toubert, A., Ruggeri, A., Fleischhauer, K., & Bonini, C. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aap9630 · Cited by 170
Cell-based therapeutic strategies for multiple sclerosis
Scolding, N. J., Pasquini, M., Reingold, S. C., Cohen, J. A., Sclerosis:, I. C. O. C.-B. T. F. M., Atkins, H., Banwell, B., Bar-Or, A., Bebo, B., Bowen, J., et al. (2017) · Brain · doi:10.1093/brain/awx154 · Cited by 170
Viral Vectors: The Road to Reducing Genotoxicity
David, R. M., & Doherty, A. T. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfw220 · Cited by 170
Cattoglio, C., Pellin, D., Rizzi, E., Maruggi, G., Corti, G., Miselli, F., Sartori, D., Guffanti, A., Di Serio, C., Ambrosi, A., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283523 · Cited by 168
Biosafety Features of Lentiviral Vectors
Schambach, A., Zychlinski, D., Ehrnstroem, B., & Baum, C. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.229 · Cited by 173
“Underlining the relevance of this goal, changes of mRNA processing following intragenic lentiviral vector integration have been associated with clonal expansion in two cases (Cavazzana-Calvo et al., 2010; Heckl et al., 2012).”
Ineffective erythropoiesis and regulation of iron status in iron loading anaemias
Camaschella, C., & Nai, A. (2016) · British Journal of Haematology · doi:10.1111/bjh.13820 · Cited by 172
Metadata
- Authors
- Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., Cavallesco, R., Gillet-Legrand, B., Caccavelli, L., Sgarra, R., Maouche-Chrétien, L., Bernaudin, F., Girot, R., Dorazio, R., Mulder, G.-J., Polack, A., Bank, A., Soulier, J., Larghero, J., Kabbara, N., Dalle, B., Gourmel, B., Socie, G., Chrétien, S., Cartier, N., Aubourg, P., Fischer, A., Cornetta, K., Galacteros, F., Beuzard, Y., Gluckman, E., Bushman, F., Hacein-Bey-Abina, S., & Leboulch, P.
- Affiliations
- Inserm (FR)
- University of Pennsylvania (US)
- Brigham and Women's Hospital (US)
- University of Trieste (IT)
- Hôpital Intercommunal de Créteil (FR)
- Hôpital Tenon (FR)
- Columbia University Irving Medical Center (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Indiana University Indianapolis (US)
- Corresponding author
- Leboulch, Philippe
- ORCID
- Venue
- Nature
- Published
- 2010-09
- Volume
- 467
- Issue
- 7313
- Pages
- 318-322
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3355472
- OpenAlex
- W2136274459
- Cited by
- 1,276
- References
- 32
- Citations by year
- 2026: 14 · 2025: 45 · 2024: 46 · 2023: 53 · 2022: 64 · 2021: 75 · 2020: 76 · 2019: 84 · 2018: 79 · 2017: 97 · 2016: 94 · 2015: 99 · 2014: 94 · 2013: 116 · 2012: 106
- FWCI
- 63.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL090921, HL090921)
- National Institute of Allergy and Infectious Diseases (AI52845, R01AI082020, R01AI052845, AI082020)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- beta-thalassemia, gene therapy, lentiviral vectors, transfusion independence, HMGA2, leukemia risk, hemoglobinopathies, sickle cell disease, hematopoietic stem cells, alternative splicing, hemoglobin
- MeSH terms
- Adolescent, Blood Cells, Blood Transfusion, Bone Marrow Cells, Child, Preschool, Clone Cells, Genetic Vectors, Homeostasis, Humans, Male, Organ Specificity, RNA, Messenger, Time Factors, Genetic Therapy, Transcriptional Activation, Gene Expression, Lentivirus, beta-Thalassemia, HMGA2 Protein, MicroRNAs, beta-Globins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.